978 related articles for article (PubMed ID: 10639120)
1. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
[TBL] [Abstract][Full Text] [Related]
2. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Rochet JC; Conway KA; Lansbury PT
Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
[TBL] [Abstract][Full Text] [Related]
4. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
5. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
6. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
[TBL] [Abstract][Full Text] [Related]
8. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
Ding TT; Lee SJ; Rochet JC; Lansbury PT
Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
[TBL] [Abstract][Full Text] [Related]
9. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
Li J; Uversky VN; Fink AL
Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
[TBL] [Abstract][Full Text] [Related]
10. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
11. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
12. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
13. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
Shtilerman MD; Ding TT; Lansbury PT
Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
[TBL] [Abstract][Full Text] [Related]
14. Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein.
Bussell R; Eliezer D
J Biol Chem; 2001 Dec; 276(49):45996-6003. PubMed ID: 11590151
[TBL] [Abstract][Full Text] [Related]
15. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
Volles MJ; Lansbury PT
Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821
[TBL] [Abstract][Full Text] [Related]
16. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
17. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
19. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
20. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
El-Agnaf OM; Jakes R; Curran MD; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]